Search

Since the first coronavirus disease 2019 (COVID-19) vaccination on December 8, 2020 in the United Kingdome (UK), more than 250,000,000 people worldwide have been vaccinated against COVID-19 in more than 100 countries as of March 5, 2021 [1]. In Korea, COVID-19 vaccinations started from February 26, 2021 among health professionals who are directly involved in treating COVID-19 patients, employees, and residents in long-term care facilities, and first-line COVID-19 responders. According to the Korean public health plan for the introduction and vaccination of COVID-19 vaccines, it is expected that vaccination will be performed in people aged ≥65 years from the second quarter and in people aged <65 with underlying diseases from the third quarter. People with comorbidities are well known as high-risk groups for COVID-19 [2]. However, there have been many questions raised about the safety, efficacy, and recommendation for COVID-19 vaccination in individuals with underlying medical conditions. This article aimed to present the efficacy and safety of each COVID-19 vaccine based on the presence and types of comorbidities, and to summarize the guidelines recommended by the World Health Organization (WHO), as well those implemented in the United States of America (USA) and the UK. [ABSTRACT FROM AUTHOR]

Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence. [ABSTRACT FROM AUTHOR]

Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence. [ABSTRACT FROM AUTHOR]

Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries. [ABSTRACT FROM AUTHOR]